99,292 Shares in ImmunityBio, Inc. $IBRX Acquired by Calamos Advisors LLC

Calamos Advisors LLC purchased a new position in ImmunityBio, Inc. (NASDAQ:IBRX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 99,292 shares of the company’s stock, valued at approximately $937,000.

Several other institutional investors have also added to or reduced their stakes in the business. Kestra Advisory Services LLC boosted its stake in shares of ImmunityBio by 4.3% during the 3rd quarter. Kestra Advisory Services LLC now owns 115,410 shares of the company’s stock worth $1,089,000 after acquiring an additional 4,780 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of ImmunityBio by 1.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 145,829 shares of the company’s stock worth $1,377,000 after purchasing an additional 2,113 shares in the last quarter. IPG Investment Advisors LLC purchased a new stake in shares of ImmunityBio in the 3rd quarter worth $210,000. Gerber Kawasaki Wealth & Investment Management purchased a new stake in shares of ImmunityBio in the 3rd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of ImmunityBio in the 3rd quarter worth $511,000. 8.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 25,000 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the sale, the director directly owned 2,777,788 shares of the company’s stock, valued at $29,861,221. This represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the sale, the director owned 100,309 shares in the company, valued at $1,053,244.50. The trade was a 44.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Trading Down 17.7%

NASDAQ IBRX opened at $7.11 on Tuesday. ImmunityBio, Inc. has a 12 month low of $1.95 and a 12 month high of $12.43. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of -7.33 and a beta of 0.17. The company’s 50 day moving average is $8.72 and its two-hundred day moving average is $7.96.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Jefferies Financial Group raised their target price on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Piper Sandler reissued an “overweight” rating and set a $16.00 price target on shares of ImmunityBio in a report on Wednesday, October 14th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a research report on Thursday, October 15th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Third-quarter net product revenue rose 53% year over year to $48.7 million, while U.S. revenue for the first nine months increased 92% to $143.6 million. ImmunityBio Q3 2026 results and approvals
• Positive Sentiment: ANKTIVA plus BCG met the primary endpoint in a randomized trial for BCG-naïve, high-grade non-muscle-invasive bladder cancer, a potential clinical and commercial catalyst. QUILT-2.005 trial results
• Positive Sentiment: The company also reported an expanded FDA label and an additional global approval for ANKTIVA, broadening its regulatory reach. ImmunityBio Q3 2026 results and approvals
• Neutral Sentiment: Trading in IBRX call options was unusually active, with volume 86% above its typical level; this does not establish a clear direction for the stock.
• Negative Sentiment: ImmunityBio reported a quarterly loss of $0.09 per share, worse than the $0.07 consensus estimate. Revenue of about $48.8 million also missed analysts’ $59.2 million forecast, and product sales declined from the prior quarter despite year-over-year growth. Q3 loss and revenue miss
• Negative Sentiment: The company disclosed “substantial doubt” about its ability to continue without additional funding, raising concerns about potential financing or dilution. The earnings miss and funding risk appear to be overshadowing the growth and pipeline news. Earnings, valuation, and funding concerns

ImmunityBio Profile

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses.

The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.